These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8067645)

  • 1. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.
    Grunstein RR; Ho KK; Sullivan CE
    Ann Intern Med; 1994 Oct; 121(7):478-83. PubMed ID: 8067645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep apnea in acromegaly.
    Grunstein RR; Ho KY; Sullivan CE
    Ann Intern Med; 1991 Oct; 115(7):527-32. PubMed ID: 1883121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of the somatostatin analog octreotide in acromegaly.
    Chanson P; Timsit J; Masquet C; Warnet A; Guillausseau PJ; Birman P; Harris AG; Lubetzki J
    Ann Intern Med; 1990 Dec; 113(12):921-5. PubMed ID: 2240917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity.
    Ip MS; Tan KC; Peh WC; Lam KS
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):477-83. PubMed ID: 11678830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
    Lim MJ; Barkan AL; Buda AJ
    Ann Intern Med; 1992 Nov; 117(9):719-26. PubMed ID: 1416573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of sleep apnoea due to acromegaly during short-term treatment with octreotide.
    Leibowitz G; Shapiro MS; Salameh M; Glaser B
    J Intern Med; 1994 Aug; 236(2):231-5. PubMed ID: 8046324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term effects of treatment with SMS 201-995 on sleep apnea syndrome associated with acromegaly].
    Esnault S; Merceur C; Kerlan V; Tea SH; le Mevel JC; Bercovici JP; Mabin D
    Neurophysiol Clin; 1989 Nov; 19(5):367-72. PubMed ID: 2615748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly.
    Herrmann BL; Wessendorf TE; Ajaj W; Kahlke S; Teschler H; Mann K
    Eur J Endocrinol; 2004 Sep; 151(3):309-15. PubMed ID: 15362959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relief of sleep apnoea after treatment of acromegaly: report of three cases and review of the literature.
    Buyse B; Michiels E; Bouillon R; Bobbaers H; Demedts M
    Eur Respir J; 1997 Jun; 10(6):1401-4. PubMed ID: 9192949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.